Analystreport

Catabasis Pharmaceuticals Inc (NASDAQ: CATB) is now covered by analysts at HC Wainwright. They set a "buy" rating and a $24.00 price target on the stock.

Catabasis Pharmaceuticals, Inc.  (CATB) 
Last catabasis pharmaceuticals, inc. earnings: 3/10 08:05 am Check Earnings Report
US:NASDAQ Investor Relations: ir.catabasis.com/investor-overview